U.S. markets closed

ACADIA Pharmaceuticals Inc. (ACAD)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
24.01+0.77 (+3.31%)
Al cierre: 04:00PM EST
23.41 -0.60 (-2.50%)
Fuera de horario: 08:00PM EST

ACADIA Pharmaceuticals Inc.

12830 El Camino Real
Suite 400
San Diego, CA 92130
United States
858 558 2871
https://www.acadia.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo597

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Stephen R. Davis J.D.President, CEO & Director1.46MN/D1961
Mr. Mark C. SchneyerExecutive VP & CFO701.03kN/D1974
Mr. Brendan P. TeehanExecutive VP, COO & Head of Commercial724.31kN/D1969
Mr. James K. KiharaVP, Chief Accounting Officer & Corporate ControllerN/DN/D1981
Mr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate CommunicationsN/DN/DN/D
Ms. Jennifer J. Rhodes J.D.Executive VP, Chief Legal Officer & SecretaryN/DN/D1970
Ms. Julie FisherSenior Vice President of Marketing & Commercial StrategyN/DN/DN/D
Ms. Holly ValdiviezSenior VP & Head of SalesN/DN/DN/D
Mr. Rob AcklesSenior VP & Chief People OfficerN/DN/DN/D
Mr. Bob MischlerSenior Vice President of New Product Planning & StrategyN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It also develops DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Gestión corporativa

La calificación ISS Governance QuickScore de ACADIA Pharmaceuticals Inc. a partir del 28 de febrero de 2024 es 9. Las puntuaciones principales son Auditoría: 8; Junta: 4; Derechos del accionista: 8; Compensación: 10.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.